ESMO 2022: Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Related Posts
-
ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab in metastatic triple-negative breast cancer
-
ASCO 2024: Improved progression-free survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer
-
ESMO 2022: Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study